List of Excipients in Branded Drug OTIPRIO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ALK-Abello Inc	OTIPRIO	otiprio	0268-8200	HYDROCHLORIC ACID
ALK-Abello Inc	OTIPRIO	otiprio	0268-8200	POLOXAMER 407
ALK-Abello Inc	OTIPRIO	otiprio	0268-8200	SODIUM CHLORIDE
ALK-Abello Inc	OTIPRIO	otiprio	0268-8200	TROMETHAMINE

Last updated: August 11, 2026

OTIPRIO is a differentiated ciprofloxacin otic product whose commercial value depends on its sterile, high-concentration, single-dose suspension rather than on a new active ingredient. Its excipient system supports local retention, suspension stability, pH control, isotonicity, and administration by health-care professionals. The most credible commercial opportunities are an authorized-generic or 505(b)(2) product, an improved otic suspension with longer post-reconstitution stability, and delivery systems that preserve single-dose dosing while lowering manufacturing cost.

OTIPRIO Excipient Strategy and Commercial Opportunities

What is OTIPRIO and how does its formulation work?

OTIPRIO is a sterile otic suspension containing ciprofloxacin hydrochloride equivalent to 6% ciprofloxacin. Otonomy developed the product for administration into the ear by a health-care professional.

The FDA-approved indications are:

• Bilateral otitis media with effusion in pediatric patients undergoing tympanostomy tube placement.
• Acute otitis externa in pediatric and adult patients six months of age and older.

OTIPRIO differs from conventional ciprofloxacin ear drops because it is administered as a single clinical dose rather than as a multi-day patient-administered regimen. The commercial proposition is based on delivery control, treatment adherence, and administration during an existing procedure.

The formulation contains ciprofloxacin hydrochloride and excipients that include povidone, polysorbate 20, sodium acetate trihydrate, acetic acid, sodium chloride, and water for injection, according to the FDA prescribing information.[1]

What excipients are used in OTIPRIO?

The principal excipient functions are summarized below.

Excipient	Likely formulation role	Commercial or regulatory significance
Povidone	Suspending, wetting, and viscosity-supporting agent	Helps maintain uniform ciprofloxacin particle distribution and may influence dose reproducibility
Polysorbate 20	Surfactant and wetting agent	Supports dispersion of hydrophobic or poorly wettable particles
Sodium acetate trihydrate	Buffer component	Helps control pH during manufacture and storage
Acetic acid	Acidifying and buffer component	Supports ciprofloxacin solubility and chemical stability
Sodium chloride	Tonicity modifier	Helps align the formulation with otic tissue tolerability requirements
Water for injection	Sterile vehicle	Supports parenteral-grade manufacturing controls even though the product is administered otically

Ciprofloxacin has pH-dependent solubility. The acidic acetate system is therefore strategically important. It can improve drug dispersion and help manage chemical degradation while maintaining an acceptable otic environment.

Povidone and polysorbate 20 perform different but complementary functions. Polysorbate 20 improves wetting and dispersion. Povidone contributes suspension stability and can modify viscosity. The balance is critical: excessive viscosity can impair delivery through the administration device, while inadequate viscosity can permit rapid settling and dose nonuniformity.

Why is OTIPRIO’s excipient strategy commercially important?

OTIPRIO’s excipient system supports four product attributes that are difficult to replicate simultaneously:

1. High ciprofloxacin loading.
2. Sterile suspension manufacture.
3. Uniform withdrawal or delivery of the intended dose.
4. Sufficient physical and chemical stability during storage and handling.

A conventional aqueous ciprofloxacin solution is easier to manufacture but does not necessarily reproduce the same local residence time or single-dose clinical workflow. A generic developer must therefore match more than the active ingredient concentration.

The key development variables include:

• Ciprofloxacin particle-size distribution.
• Crystal form and crystallinity.
• Povidone grade and molecular weight.
• Polysorbate concentration and peroxide content.
• Buffer capacity and final pH.
• Sedimentation rate and redispersibility.
• Viscosity under administration conditions.
• Sterility assurance and container-closure integrity.
• Extractables and leachables from the vial and delivery components.

These variables may create formulation and manufacturing barriers even where the active ingredient is off-patent.

What formulation patents could protect an OTIPRIO follow-on product?

Protection for a product such as OTIPRIO can arise from several patent categories:

Composition and suspension patents

A patent may claim a specific ciprofloxacin concentration, particle-size range, excipient ratio, pH range, viscosity range, or sedimentation profile. Narrow claims directed to a defined combination of povidone, polysorbate, acetate buffer, and ciprofloxacin could be relevant to a follow-on developer.

Method-of-use patents

Method claims may cover single-dose administration during tympanostomy tube placement or treatment of otitis externa using a defined concentration and administration volume.

Device and administration patents

Claims may cover a vial, applicator, cannula, syringe, or dosing method that delivers a sterile suspension into the middle ear or external auditory canal.

Manufacturing patents

Manufacturing claims may cover sterile milling, aseptic blending, particle-size control, suspension filling, or reconstitution procedures. These patents can impose practical barriers even when a competitor uses different excipients.

The commercial analysis should distinguish between patents listed in the FDA Orange Book and unlisted patents. Orange Book-listed patents can support a Paragraph IV certification and statutory litigation stay. Unlisted formulation, process, or device patents may still support infringement litigation but do not necessarily create the same ANDA timing consequences.

What is the FDA regulatory status of OTIPRIO?

OTIPRIO was approved by the FDA in December 2015 under NDA 210825.[1] It is a small-molecule drug, not a biologic. Biosimilar pathways therefore do not apply.

A follow-on developer would generally assess two routes:

Route	Strategic use	Main burden
505(j) ANDA	Pursue therapeutic equivalence to the reference product	Demonstrate pharmaceutical equivalence, bioequivalence or equivalent performance, and manufacturing comparability
505(b)(2) NDA	Introduce formulation, delivery, dosing, or clinical-use differences	Requires a new NDA and may require additional clinical or local-tolerability data

For a sterile otic suspension, the ANDA route may be more difficult than for a simple oral solution. FDA review can focus on particle attributes, formulation sameness, dose delivery, microbiological quality, and product performance. A materially different excipient system could move the program toward 505(b)(2).

When did OTIPRIO lose exclusivity?

Ciprofloxacin is an established active ingredient, so OTIPRIO did not receive new chemical entity exclusivity. Any product-specific regulatory exclusivity would have depended on the approval basis and qualifying clinical investigations.

The relevant commercial dates are:

Event	Date
FDA approval of OTIPRIO	December 2015
Likely end of ordinary three-year new-clinical-investigation exclusivity, if granted	December 2018
Patent-based entry date	Dependent on listed and unlisted patent rights
Otonomy strategic wind-down	2022 onward

The product’s current commercial availability and any remaining intellectual-property rights should be evaluated separately. Regulatory approval does not guarantee continuing commercial supply. Otonomy’s wind-down materially changes the business case for licensing, acquisition, authorized supply, or independent development.

What is the Orange Book status of OTIPRIO?

The Orange Book analysis should address four questions:

1. Whether NDA 210825 has active patent listings.
2. Whether listed patents cover the drug substance, formulation, method of use, or device.
3. Whether the listed patents have expired or remain enforceable.
4. Whether any patents have pediatric exclusivity or other term adjustments.

A definitive current patent table requires a live review of the FDA Orange Book and Drugs@FDA records. The FDA label confirms the NDA and approved indications but does not establish the full current patent estate.[1,2]

For a generic applicant, the relevant filing certifications would include:

• Paragraph I, if no patent information has been submitted.
• Paragraph II, if listed patents have expired.
• Paragraph III, if the applicant will wait for patent expiration.
• Paragraph IV, if the applicant asserts that listed patents are invalid, unenforceable, or not infringed.

No biosimilar challenge is relevant because OTIPRIO is not a biologic.

Which companies are challenging OTIPRIO?

Publicly visible competitive pressure is more likely to come from generic ciprofloxacin otic products, compounded otic preparations, and alternative fluoroquinolone products than from biosimilar developers.

Potential competitors include:

• Generic ciprofloxacin ophthalmic solutions used off-label in otic settings.
• Ciprofloxacin and dexamethasone otic suspension products.
• Ofloxacin otic solution.
• Combination antibiotic-steroid ear drops.
• Hospital or specialty-pharmacy compounded preparations.
• Future ANDA or 505(b)(2) products designed to replicate single-dose administration.

The most direct competitive threat is a product that matches OTIPRIO’s concentration and procedural use while offering a lower acquisition cost. A standard ciprofloxacin solution may compete on price but does not necessarily replicate the same administration model.

What commercial opportunities exist for OTIPRIO excipients?

Authorized generic or licensed supply

The simplest opportunity is manufacture of an OTIPRIO-equivalent product under license or as an authorized generic. The value would depend on access to the reference formulation, analytical methods, manufacturing process, regulatory dossier, and remaining market demand.

505(b)(2) sustained-retention otic suspension

A developer could use the OTIPRIO concept but modify the suspension system to increase middle-ear residence time or reduce procedural dosing volume. Candidate strategies include:

• Higher-viscosity polymer systems.
• Mucoadhesive polymers.
• In situ gelling excipients.
• Controlled-release microparticles.
• Lipid or polymeric depot systems.

The regulatory advantage is product differentiation. The disadvantage is a greater need for local-tolerability, pharmacokinetic, and clinical-performance data.

Preservative-free multidose systems

OTIPRIO’s single-dose model avoids many preservative-exposure concerns. A competing product could pursue a preservative-free multidose container with a validated sterile dispensing system. The opportunity is convenience and reduced packaging waste, but device integrity and microbial-control requirements become central.

Room-temperature stability

A formulation that improves storage stability could reduce logistics costs for clinics and ambulatory surgery centers. The main technical targets would be:

• Reduced sedimentation.
• Improved redispersibility.
• Lower sensitivity to temperature excursions.
• Lower polysorbate oxidation.
• Consistent ciprofloxacin potency and impurity profile.

Lower-cost excipient substitution

Povidone, surfactant, and buffer substitution could lower cost or simplify supply. Such substitution is commercially attractive only if it preserves particle wetting, suspension uniformity, sterility, delivery performance, and otic tolerability.

How strong is the OTIPRIO patent estate?

The strength of the estate depends less on ciprofloxacin itself than on the scope and enforceability of formulation, use, process, and device claims.

Estate element	Likely strength
Ciprofloxacin active ingredient	Weak, because the compound is long established
Specific high-concentration suspension	Potentially moderate to strong if claims have narrow, reproducible boundaries
Excipient combination	Moderate if the combination produces demonstrated stability or delivery advantages
Single-dose tympanostomy use	Potentially meaningful, subject to claim scope and prior art
Manufacturing process	Stronger against manufacturers using the same process, weaker against design-arounds
Delivery device	Relevant if the device is necessary for the claimed dose or administration method

The principal design-around opportunities are changing polymer grade, surfactant identity, particle-size distribution, buffer composition, or delivery hardware. A competitor may also pursue a solution formulation or a different concentration through 505(b)(2).

What generic launch risks exist for OTIPRIO?

The principal risks are:

• Patent litigation after a Paragraph IV filing.
• Failure to demonstrate suspension uniformity.
• Inability to match the reference product’s particle attributes.
• Inconsistent dose delivery through the proposed device.
• Sterility or container-closure failures.
• Local irritation or ototoxicity concerns.
• Low commercial demand after launch.
• Dependence on surgeon and ambulatory-surgery-center adoption.
• Competition from inexpensive generic ophthalmic or otic ciprofloxacin products.

The commercial opportunity is strongest where the buyer values procedural efficiency and treatment adherence. It is weaker in price-sensitive settings where clinicians can substitute low-cost multi-day ear drops.

What is the investment case for an OTIPRIO follow-on?

A follow-on program is commercially attractive if it can achieve at least one of four outcomes:

1. Reduce product cost materially.
2. Preserve single-dose administration.
3. Improve storage or handling.
4. Obtain differentiated claims for retention, dosing, or clinical workflow.

A pure formulation copy without a clear cost or supply advantage faces limited upside. A product with a validated manufacturing advantage, reliable sterile supply, and a clean patent position could support licensing to a generic manufacturer, specialty pharmaceutical company, or ear, nose, and throat-focused commercial platform.

Key Takeaways

• OTIPRIO is a 6% ciprofloxacin sterile otic suspension approved under NDA 210825.
• Its excipient strategy uses povidone, polysorbate 20, acetate buffering, sodium chloride, and sterile water to support suspension stability, wetting, pH control, tonicity, and dose delivery.
• The principal intellectual-property value lies in formulation, use, process, and device claims rather than in ciprofloxacin.
• The most practical follow-on routes are an authorized generic, a 505(j) equivalent, or a differentiated 505(b)(2) otic delivery system.
• Biosimilar risk does not apply.
• Generic risk is driven by formulation replication, Paragraph IV exposure, low-cost ciprofloxacin substitutes, and the product’s post-Otonomy commercial status.
• Excipient substitution is commercially viable only if it preserves sterility, particle attributes, redispersibility, local tolerability, and administration performance.

FAQs

Can a generic company use different excipients from OTIPRIO?

Yes, but the developer must establish pharmaceutical equivalence or justify the difference through the applicable FDA pathway. Material excipient changes can affect suspension behavior, drug release, local tolerability, and regulatory classification.

Is OTIPRIO interchangeable with ciprofloxacin ophthalmic solution?

Not automatically. A clinician may use products off-label, but therapeutic substitution and FDA-approved interchangeability depend on the specific product, indication, labeling, and applicable regulatory determinations.

Does OTIPRIO require a preservative?

The labeled formulation is a single-dose sterile suspension and does not rely on a conventional multidose preservative system. A follow-on multidose product would require a different microbial-control strategy.

Could an in situ gel replace OTIPRIO?

Potentially. An in situ gel could improve retention and reduce runoff, but it would likely require a 505(b)(2) strategy if the formulation, administration, or clinical performance differs materially from the reference product.

Are OTIPRIO excipients themselves patentable?

Individual excipients such as povidone, polysorbate 20, sodium chloride, and acetate buffer are established materials. Patentability would more likely arise from a novel combination, concentration range, particle system, manufacturing process, or demonstrated delivery performance.

References

1. U.S. Food and Drug Administration. (2015). OTIPRIO (ciprofloxacin otic suspension) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: OTIPRIO, NDA 210825.
3. U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2019). Generic drug user fee amendments: Product-specific guidance for industry.
5. United States Pharmacopeia. (2023). General chapter <797>: Pharmaceutical compounding: Sterile preparations.